Home / Business and Economy / India Tightens Drug Quality Rules, Halting Bad Batches
India Tightens Drug Quality Rules, Halting Bad Batches
4 Nov
Summary
- New rules mandate immediate suspension of drug manufacturing licenses for quality failures.
- Suspensions will last until manufacturers implement corrective actions satisfactory to regulators.
- Stricter oversight follows concerns over child deaths linked to Indian-made cough syrups.
India is set to implement stricter regulations for its pharmaceutical sector, proposing rules that would require immediate suspension of manufacturing licenses for drugs failing specified quality standards. This move aims to expedite regulatory action, as current processes can create a time lag, allowing substandard drugs to remain in circulation and posing public health risks.
The proposed rules specifically target failures in impurity levels, sterility, assay, or dissolution. A license suspension will persist until manufacturers demonstrate effective root-cause analysis and implement corrective and preventive actions that satisfy regulators. License restoration will only occur after these measures are verified.
This enhanced oversight comes in the wake of increased global scrutiny, particularly after locally manufactured cough syrups were associated with child fatalities in several countries. The Central Drugs Standard Control Organisation regularly identifies drug samples that do not meet prescribed standards. The new regulations will empower the central licensing authority to demand investigation reports and corrective action details from manufacturers and state regulators.
